Nuvectis Pharma, Inc.
Data quality: 83%
NVCT
Nasdaq
Manufacturing
Chemicals
$8.16
▲
$0.02
(0.25%)
Mkt Cap: 216.17 M
Price
$8.16
Mkt Cap
216.17 M
Day Range
$7.94 — $8.17
52-Week Range
$5.55 — $11.52
Volume
17,883
Open $8.14
50D / 200D Avg
$8.53
4.37% below
50D / 200D Avg
$7.33
11.39% above
Quick Summary
Key Takeaways
Negative free cash flow of -16.01 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-129.36%
Below sector avg (-53.41%)
ROIC-106.57%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio3.07
Interest CoverageN/A
Valuation
PE (TTM)
-8.18
Below sector avg (-1.48)
P/B Ratio9.00
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -8.2 | -1.5 |
| P/B | 9.0 | 1.6 |
| ROE % | -129.4 | -53.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -26.44 M |
| ROE | -129.36% | ROA | -84.49% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -16.01 M |
| ROIC | -106.57% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 3.07 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 24.01 M | Tangible Book Value | 24.01 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -8.18 | Forward P/E | N/A |
| P/B Ratio | 9.00 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -7.41% | ||
| Market Cap | 216.17 M | Enterprise Value | 180.73 M |
| Per Share | |||
| EPS (Diluted TTM) | -1.32 | Revenue / Share | N/A |
| FCF / Share | -0.60 | OCF / Share | -0.60 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 60.54% |
| SBC-Adj. FCF | -21.83 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Net Income | -26.44 M | -19.00 M | -22.26 M | -19.09 M |
| EPS (Diluted) | -1.32 | -1.11 | -1.43 | -1.51 |
| Gross Profit | — | — | — | — |
| Operating Income | -27.57 M | -19.85 M | -22.90 M | -19.23 M |
| EBITDA | — | — | — | — |
| R&D Expenses | 18.15 M | 12.92 M | 15.38 M | 13.23 M |
| SG&A Expenses | — | — | — | — |
| D&A | — | — | — | — |
| Interest Expense | — | — | — | — |
| Income Tax | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Total Assets | 31.71 M | 18.61 M | 19.19 M | 20.41 M |
| Total Liabilities | 13.30 M | 8.89 M | 6.98 M | 6.19 M |
| Shareholders' Equity | 18.41 M | 9.71 M | 12.20 M | 14.22 M |
| Total Debt | — | — | — | — |
| Cash & Equivalents | 31.63 M | 18.53 M | 19.13 M | 19.99 M |
| Current Assets | 31.71 M | 18.61 M | 19.19 M | 20.41 M |
| Current Liabilities | 13.30 M | 8.89 M | 6.98 M | 6.19 M |
{"event":"ticker_viewed","properties":{"ticker":"NVCT","listing_kind":"stock","pathname":"/stocks/nvct","exchange":"Nasdaq","country":"US"}}